We report a multicity outbreak of cfr-containing linezolidresistant Staphylococcus epidermidis in Ohio. Thirty-nine isolates were obtained from 2 hospitals. Two clones with different mechanisms of linezolid resistance were circulating in hospital A. One of these contained the cfr gene, and the other a ribosomal mutation. The clone containing cfr was identical in both hospitals.
We report a multicity outbreak of cfr-containing linezolidresistant Staphylococcus epidermidis in Ohio. Thirty-nine isolates were obtained from 2 hospitals. Two clones with different mechanisms of linezolid resistance were circulating in hospital A. One of these contained the cfr gene, and the other a ribosomal mutation. The clone containing cfr was identical in both hospitals.
Linezolid is an oxazolidinone antibacterial approved for treatment of infections caused by several gram-positive organisms, including Staphylococcus aureus and Staphylococcus epidermidis [1] . Since its clinical introduction in the United States in 2000, the emergence of resistant strains has remained relatively rare [2] [3] [4] . Several multicenter and multinational surveillance studies have shown that 199% of clinical strains of coagulase negative staphylococci and S. aureus still remain susceptible to linezolid [2] [3] [4] [5] [6] [7] . When resistance does occur, it is seen most commonly in coagulase-negative staphylococci and enterococci [4, [7] [8] [9] . Resistance may arise during therapy, especially in deep-seated infections treated over prolonged courses [8, 9] . Most isolates of this type in both enterococci and staphylococci have mutations at the site of action, in the central loop of domain V of the 23S rRNA; the most common of these mutations is G2576T [10] . Recently, linezolid resistance due to acquisition of a gene known as cfr (chloramphenicol and florfenicol resistance) has been reported [11] [12] [13] [14] [15] [16] [17] . The product of this gene is a methyltransferase that modifies adenosine at position 2503 in the 23S rRNA, which is located in the drugbinding site.
This methylation affects the binding of and susceptibility to 4 other antimicrobial classes (phenicols, lincosamides, pleuromutilins, and streptogramin A), leading to a multidrug-resistant phenotype. The cfr gene has been found primarily on plasmids, and in the laboratory, it can transfer between staphylococci [13] . Although the first human isolate was found to have a chromosomal location, flanking regions suggested a plasmidic origin [14] . The cfr gene was first seen in veterinary isolates of Staphylococcus warneri, Staphylococcus sciuri, Staphylococcus hyicus, and S. aureus perhaps associated with veterinary use of phenicols [18] , but it has also been reported in several isolates of S. aureus from humans, including an outbreak in Spain [19] . The epidemiology of linezolid-resistant coagulase-negative staphylococci has not been well characterized. However, 2 nosocomial outbreaks of such organisms have occurred that have been associated with clonal spread [20, 21] . We describe here the clinical and molecular epidemiology of an outbreak of linezolid-resistant S. epidermidis containing cfr in 2 hospitals located 39 miles apart in northeastern Ohio. Susceptibility testing, molecular typing, and mechanistic studies were performed in a central laboratory.
Methods. This study was conducted in a 280-bed, rural, county hospital with an on-site-affiliated, long-term acute care (LTAC) facility, located in northeast Ohio (hospital A). The patients in this LTAC facility often have multiple comorbidities, with a mean hospital stay of 25 days. An index isolate of linezolid-resistant S. epidermidis was isolated from a patient's blood in April 2008. From then until May 2009, isolates of linezolid-resistant S. epidermidis from blood cultures were stored in a Ϫ70ЊF freezer. Demographic data, current and prior hospitalizations over the prior 12 months, comorbidities, and antibacterial use during the prior 6 months were recorded by reviewing patient medical and pharmacy records. The clinical events were classified as nosocomial acquired (148 h after admission) or community acquired (!48 h after admission). Bacteremic episodes were classified as true infection on the basis of the following criteria: multiple positive blood culture results, a positive blood culture result along with a positive culture result with the same organism from an infected device or line, and bacteremia associated with systemic symptoms (fever [temperature 18 .5ЊC], hypotension [systolic blood pressure !90 mm/Hg], and leukocytosis [113,000 cells/mL]) that could not be attributed to other processes [22] . The linezolid-resistant bacterial isolates recovered were referred to the antibacterial department at Pfizer Global Research and Development in Groton, Connecticut (the central laboratory), for confirmation of species identification, minimum inhibitory concentrations (MICs), clonal analysis, and characterization of the mechanisms underlying linezolid resistance. Because our central laboratory had been sent previous linezolidresistant S. epidermidis isolates from this part of Ohio, we were aware of similar cases occurring in another Ohio hospital 39 miles away (hospital B). The first such case actually occurred there in 2006, 2 years prior to our index case. Isolates that had been recovered during the period from October 2006 to July 2007 were obtained from hospital B. Hospital B is a larger medical facility; with 476 bed, it serves 8 outpatient medical centers and has an on-site, 30-bed LTAC facility. Although we could obtain isolates from hospital B, clinical information was not available. To the best of our knowledge, no patients from hospital B have been admitted to hospital A or its LTAC facility in the previous 5 years. Antimicrobial susceptibility testing of bacterial isolates was performed according to the Clinical and Laboratory Standards Institute's approved methods [23, 24] . Pulsed-field gel electrophoresis (PFGE) was performed using a modification of the method of McDougal et al [25] . The criteria for clonality were those used by Tenover et al [26] . Presence of the cfr-methylase gene (ie, G2576T) and L4 mutations of the 50S ribosomal subunit were confirmed by polymerase chain reaction analysis. Less common ribosomal mutations, such as T2500A, were not tested for.
Results and discussion. PFGE typing of 15 isolates from hospital A revealed an interesting gel pattern (Figure 1 ). First, 2 major clone types were circulating in hospital A. Type 1 was generally cfr positive and had no G2576T mutation. Type 2 was generally cfr negative but had G2576T mutations. In addition, linezolid-resistant isolates from hospital B also belonged to the same pulsotype as type 1 from hospital A. These isolates were mostly, but not universally, cfr positive. Exceptions at hospital A included a type 1 isolate that was both cfr negative and G2576T negative, and a type 2 isolate that was positive for cfr. We did not find any isolates carrying both the cfr gene and the G2576T ribosomal mutation. The majority of the isolates from both clonal types were found to also possess a concomitant glycine insertion in a highly conserved region of the L4 ribosomal gene: 71 GR 72 to 71 GGR 72 . This glycine insertion has been described once before in S. epidermidis, where it was the only mutation thought to explain linezolid resistance [27] . The exact contribution of this insertion to linezolid resistance is difficult to discern in strains with underlying cfr or G2576T mutations. It is interesting to note that a few strains from both medical centers demonstrated only L4 mutations and had high MICs of linezolid (1256 mg/mL). However, in these strains, it should be noted that other, less common linezolid-resistant mutations (L3, L22, and T2500A) were not tested for. Bacterial isolates were recovered from both medical centers (18 isolates from hospital A and 21 isolates from hospital B). In hospital A, 16 strains were identified as S. epidermidis, and 2 strains were identified as Staphylococcus haemolyticus. These strains were isolated from blood cultures from 11 different patients. Because S. epidermidis cases predominated, we focused our attention on those isolates. Medical records from these patients were reviewed. Six were females with a mean age of 64 years (range, 34-83 years). All had comorbidities. The most common of these comorbidities were diabetes mellitus, hypertension, cardiovascular disease, and malignancies. Eight of the 11 isolates were nosocomially acquired, and the remaining 3 were acquired in the LTAC facility. Bacteremia was considered a true infection on the basis of the criteria outlined above in 5 of 11 patients. Of these 5 cases of bacteremia, 3 were associated with central line use. All patients had received antibacterials 5-13 days prior to the bacteremic episode, and 5 had received linezolid. None had received other agents that might select cfr, such as clindamycin or chloramphenicol. Pharmacy records showed that all patients with a linezolid-resistant isolate had received linezolid treatment within the previous 6 months.
Bacterial identification, antibiograms, molecular typing data, and molecular mechanistic data from isolates in hospital A are summarized in Table 1 , and those from hospital B in Table 2 . It is noteworthy that 194% of isolates in both medical centers, independent of the resistance mechanism, had linezolid MICs 1256 mg/mL. As expected, the cfr-positive isolates in both medical centers also displayed a multidrug-resistant phenotype, including resistance to clindamycin and chloramphenicol.
There are both infection control and mechanistic implications to our observations. LTAC facilities have been implicated as reservoirs in regional outbreaks of multidrug-resistant organisms [28] . The majority of our patients had multiple risk factors for colonization and/or infection with multidrug-resistant organisms, including multiple comorbidities, presence of intravascular catheter, and prior antibacterial exposure [21, 29, 30] . All patients received linezolid at some point during the prior 6 months, which may have contributed to the emergence of resistant strains [8, 31, 32] . Two major clones were circulating in hospital A, and the one containing cfr was common to both hospitals. We believe that the cfr strain may have originated in hospital B. Hospital B is a larger facility, and resistant strains were originally identified there 2 years earlier. Although the 2 hospitals are not affiliated, they are close enough to one another that it is possible that some patients may have received care in both. Unfortunately, because of the absence of clinical information from hospital B, we can neither confirm nor refute this hypothesis. The demonstration that the clone in both hospitals contained cfr is disturbing, because this gene is usually plasmid mediated, raising the concern about spread between strains in addition to clonal spread. Plasmid studies as well as attempts to elucidate the exact role of the L4 insertion and other less common resistance mutations in mediating linezolid resistance in these strains are the subject of ongoing work in our laboratories. Strains with L4 mutations may be more common than previously thought, because they are not always tested for. Recent reports have shown L4 mutations in laboratory strains of linezolid-resistant S. aureus [33] as well as in pneumococci from humans [34] and Clostridium species from animals [35] .
